Venus Concept (VERO)
OTHER OTC:VERO
Top Page
Venus Concept
(OTC:VERO)
Select Model
Select Model
Rating:41Neutral
Price Target:
$1.00
▼(-34.64% Downside)
Action:UpgradedDate:02/04/26
The score is pressured primarily by weak financial performance (declining revenue, large losses, high leverage and cash burn). Technicals also point to a sustained downtrend with negative momentum. Earnings updates show some product and balance-sheet progress, but near-term results remain negative, and corporate events (delisting and reliance on bridge financing/covenant relief) add meaningful risk.
Positive Factors
FDA-cleared multi-application platform
510(k) clearance for Venus Nova establishes a regulated, multi-application device that can drive equipment placements, recurring consumable sales and service contracts. Over months this supports revenue diversification, product-led growth and a clearer commercialization path for sustained installed-base monetization.
Negative Factors
Very high leverage
A debt-to-equity ratio near 2.84 indicates substantial leverage that raises refinancing, interest and solvency risk. With ongoing operating losses and limited equity buffer, high debt constrains strategic choices, increases fixed financial burdens, and elevates the probability that future cash flows must be directed to debt service rather than growth initiatives.
Read all positive and negative factors
Positive Factors
Negative Factors
FDA-cleared multi-application platform
510(k) clearance for Venus Nova establishes a regulated, multi-application device that can drive equipment placements, recurring consumable sales and service contracts. Over months this supports revenue diversification, product-led growth and a clearer commercialization path for sustained installed-base monetization.
Read all positive factors
Venus Concept (VERO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$570.94K
Dividend YieldN/A
Average Volume (3M)141.32K
Price to Earnings (P/E)―
Beta (1Y)1.41
Revenue Growth-12.39%
EPS Growth44.61%
CountryUS
Employees292
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-12.14
Shares Outstanding1,859,123
10 Day Avg. Volume313,727
30 Day Avg. Volume141,323
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.24
Price to Sales (P/S)0.05
P/FCF Ratio-0.26
Enterprise Value/Market Cap47.83
Enterprise Value/Revenue0.46
Enterprise Value/Gross Profit0.72
Enterprise Value/Ebitda-0.60
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-5.01
Revenue Forecast (FY)$65.80M
Venus Concept Business Overview & Revenue Model
Company Description
Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its pr...
How the Company Makes Money
Venus Concept generates revenue through a diversified model that includes the sale of its medical devices, recurring service and maintenance contracts, and consumable products associated with its devices. The company sells its aesthetic devices to...
Venus Concept Earnings Call Summary
Earnings Call Date:Nov 13, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Apr 06, 2026
Earnings Call Sentiment Negative
While the launch of Venus Nova and improvements in the balance sheet are positive developments, the company faces significant challenges with declining overall revenue, increased losses, and ongoing difficulties with the Venus Hair business. The financial outlook remains uncertain.Positive Updates
Launch of Venus Nova
Venus Concept announced the 510 clearance for Venus Nova, the first product from their new focused R&D strategy. Venus Nova is designed to redefine noninvasive treatments and is expected to contribute to the company's long-term growth.
Negative Updates
Overall Revenue Decline
Total revenue decreased by 8% year over year to $13.8 million, with notable declines in U.S. revenue (12%) and international revenue (3%).
Read all updates
Q3-2025 Updates
Positive
Negative
Launch of Venus Nova
Venus Concept announced the 510 clearance for Venus Nova, the first product from their new focused R&D strategy. Venus Nova is designed to redefine noninvasive treatments and is expected to contribute to the company's long-term growth.
Read all positive updates
Company Guidance
During the third quarter of 2025, Venus Concept Inc. reported a total revenue of $13.8 million, reflecting an 8% year-over-year decline, with U.S. revenue decreasing by 12% and international revenue by 3%. Despite a 2% increase in sales of energy-based devices (EBD) to $9.5 million, the overall revenue was negatively impacted by a 12% decrease in product systems revenue, a 15% decrease in other product revenue, and a 5% decrease in services revenue. The company's gross profit decreased by 11% to $8.8 million, with the gross margin declining to 64% from 66.1% in the previous year, primarily due to U.S. tariffs and higher manufacturing costs. Operating expenses rose by 7% to $18.3 million, driven partly by legal fees related to the pending sale of the Venus Hair business. The net loss attributable to stockholders was $22.6 million, or $12.14 per share, compared to a net loss of $9.3 million, or $13.1 per share, in 2024. The adjusted EBITDA loss was $7.8 million, up from $5.9 million the previous year. As of September 30, 2025, the company held cash and cash equivalents of $5.9 million, with total debt obligations reduced to approximately $30.1 million from $39.7 million as of December 31, 2024. Despite these challenges, the company anticipates sequential growth in the fourth quarter, supported by the limited commercial launch of the Venus Nova system in December.Venus Concept Financial Statement Overview
Summary
Income Statement
30
Negative
Balance Sheet
25
Negative
Cash Flow
35
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 58.88M | 64.83M | 76.35M | 99.50M | 105.62M | 78.01M |
| Gross Profit | 37.89M | 44.31M | 52.17M | 65.97M | 74.09M | 51.39M |
| EBITDA | -45.42M | -36.04M | -26.11M | -35.28M | -13.04M | -68.49M |
| Net Income | -54.61M | -47.00M | -37.25M | -43.70M | -23.01M | -81.71M |
Balance Sheet | ||||||
| Total Assets | 61.62M | 68.18M | 93.65M | 125.38M | 157.37M | 160.53M |
| Cash, Cash Equivalents and Short-Term Investments | 5.93M | 4.27M | 5.40M | 11.57M | 30.88M | 34.30M |
| Total Debt | 32.67M | 43.03M | 79.70M | 83.77M | 77.87M | 79.60M |
| Total Liabilities | 58.49M | 65.35M | 107.10M | 116.64M | 115.78M | 116.76M |
| Stockholders Equity | 2.67M | 2.37M | -14.02M | 8.09M | 40.94M | 44.23M |
Cash Flow | ||||||
| Free Cash Flow | -20.75M | -11.19M | -12.97M | -27.32M | -20.28M | -28.94M |
| Operating Cash Flow | -20.45M | -11.07M | -12.86M | -26.98M | -19.77M | -28.65M |
| Investing Cash Flow | -294.00K | -123.00K | -116.00K | -336.00K | -552.00K | -2.39M |
| Financing Cash Flow | 22.19M | 10.06M | 6.80M | 8.01M | 16.82M | 49.67M |
Venus Concept Technical Analysis
Negative
1.53
Price Trends
0.95
Negative
1.39
Negative
1.90
Negative
Market Momentum
-0.12
Negative
40.01
Neutral
47.69
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VERO, the sentiment is Negative. The current price of 1.53 is above the 20-day moving average (MA) of 0.36, above the 50-day MA of 0.95, and below the 200-day MA of 1.90, indicating a bearish trend. The MACD of -0.12 indicates Negative momentum. The RSI at 40.01 is Neutral, neither overbought nor oversold. The STOCH value of 47.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VERO.
Venus Concept Risk Analysis
Venus Concept disclosed 46 risk factors in its most recent earnings report. Venus Concept reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Venus Concept Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $13.92M | -0.43 | 20.03% | ― | -99.28% | -46.17% | |
45 Neutral | $3.05M | -0.28 | -191.39% | ― | ― | 76.53% | |
42 Neutral | $1.89M | -0.18 | -145.52% | ― | ― | 97.70% | |
42 Neutral | $419.00 | -0.95 | ― | ― | ― | ― | |
41 Neutral | $570.94K | -0.05 | -2268.26% | ― | -12.39% | 44.61% |
* Healthcare Sector Average
VERO
Venus Concept
0.31
-3.34
-91.59%
AEMD
Aethlon Medical
2.32
-29.77
-92.77%
PAVM
PAVmed
9.30
-13.74
-59.64%
BBLG
Bone Biologics
1.14
-3.91
-77.43%
BJDX
Bluejay Diagnostics
1.94
-13.42
-87.37%
DHAI
DIH Holdings US, Inc Class A
0.03
-6.45
-99.54%
Venus Concept Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Venus Concept extends bridge financing and eases covenants
Negative
Feb 3, 2026
On January 29, 2026, Venus Concept Inc. and its subsidiaries entered into a consent agreement with Madryn Health Partners that temporarily waived certain minimum liquidity requirements under the company’s Main Street Priority Loan through Fe...
Business Operations and StrategyDelistings and Listing ChangesPrivate Placements and FinancingRegulatory Filings and Compliance
Venus Concept to Voluntarily Delist and Deregister Shares
Negative
Jan 21, 2026
On January 14, 2026, Venus Concept Inc. and its subsidiaries entered into a consent agreement and a twenty-fourth amendment to their existing loan arrangements with Madryn Health Partners, waiving certain minimum liquidity requirements and extendi...
Business Operations and StrategyPrivate Placements and Financing
Venus Concept Secures Short-Term Debt Relief Extension
Neutral
Jan 7, 2026
On December 31, 2025, Venus Concept Inc. and several of its subsidiaries entered into a Consent Agreement with Madryn Health Partners and its affiliate, providing temporary relief under the company’s Main Street Priority Loan by waiving cert...
Private Placements and Financing
Venus Concept Amends Loan Agreement with Madryn Health
Neutral
Dec 2, 2025
On November 30, 2025, Venus Concept Inc. and its subsidiaries entered into a Consent Agreement with Madryn Health Partners to waive certain liquidity requirements and allow cash interest payments to be applied to outstanding principal balances. Ad...
Business Operations and StrategyFinancial DisclosuresM&A TransactionsPrivate Placements and FinancingProduct-Related Announcements
Venus Concept Gains FDA Clearance for Venus Nova
Neutral
Nov 13, 2025
On November 10, 2025, Venus Concept announced it received 510(k) clearance from the FDA to market Venus Nova, its new multi-application platform for non-invasive treatments. The announcement is part of the company’s strategic efforts to stab...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.